Tenofovir alafenamide tablets (Vemlidy) price forecast in 2025

Tenofovir alafenamide fumarate tablets (Vemlidy/Vemlidy) is an oral antiviral drug widely used in the treatment of chronic hepatitis B (HBV) and has been included in the recommendations of guidelines in many countries around the world. Its core applications are mainly focused on patients with active chronic hepatitis B, risk of liver fibrosis, active viral replication or risk of disease progression. Due to its stronger liver targeting, lower dosage, and higher safety in kidney and bone metabolism, Vemlidy is particularly suitable for patients who require long-term antiviral treatment, including the elderly and those with potential kidney risks.

In clinical application,Vemlidy is usually used as a long-term maintenance treatment drug to continuously inhibit HBV replication and keep the patient's viral load within a controllable range, thereby reducing the risk of cirrhosis, liver failure and other risks. For young patients or people with long-term work pressure and need to maintain a higher quality of life, Vemlidy's high tolerability and low side effects are more practical. Many experts believe that this dosage form of tenofovir is more suitable for modern and long-term hepatitis B management needs.

In terms of price,Vemlidy has been launched as the original drug in China and has been included in Class B medical insurance, reducing the financial pressure on patients. At present, the common specification on the market is 25mg*30 tablets. The actual payment after medical insurance is about 500 yuan, which varies depending on the city. Compared with domestic prices, the price of overseas original Vemlidy is significantly higher. The same specifications often exceed US$1,000 in markets such as the United States. This gap mainly comes from differences in brand pricing, market environment and medical systems.

At the same time, for patients with overseas purchasing needs, generic Vemlidy drugs from India, Laos and other regions have become a more price-competitive choice. The core ingredients of the generic version produced by pharmaceutical companies such as Mylan of India and Lucius of Laos are consistent with the original drug, and the production process also complies with international regulatory requirements. The price is only around 100 yuan, which can significantly reduce the economic pressure of long-term treatment.

Reference materials:https://www.vemlidyhcp.com/